NYSE: ANROAlto Neuroscience Inc Stock
$3.91+0.01 (+0.26%)
Updated Dec 6, 2024
ANRO Price
$3.91
Fair Value Price
N/A
Market Cap
$105.45M
52 Week Low
$3.61
52 Week High
$24.00
P/E
-0.79x
P/B
0.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.45M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$46M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANRO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
C
Sentiment
D
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANRO
Ranked#417 of 554
Ranked#417 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important ANRO news, forecast changes, insider trades & much more!
ANRO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANRO is good value based on its book value relative to its share price (0.64x), compared to the US Biotechnology industry average (5.68x)
P/B vs Industry Valuation
ANRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ANRO due diligence checks available for Premium users.
Valuation
ANRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.79x
Industry
-105.55x
Market
29.86x
ANRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
5.68x
ANRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.8M
Profit Margin
0%
ANRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$191.6M
Liabilities
$26.6M
Debt to equity
0.16
ANRO's short-term assets ($183.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANRO's short-term assets ($183.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.7M
Investing
-$1.0M
Financing
$1.3M
ANRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANRO vs Biotech Stocks
Alto Neuroscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.